article atm-icon bar bell bio cancel-o cancel ch-icon crisis-color crisis cs-icon doc-icon down-angle down-arrow-o down-triangle download email-small email external facebook googleplus hamburger image-icon info-o info instagram left-angle-o left-angle left-arrow-2 left-arrow linkedin loader menu minus-o pdf-icon pencil photography pinterest play-icon plus-o press right-angle-o right-angle right-arrow-o right-arrow right-diag-arrow rss search tags time twitter up-arrow-o videos

Suggested Content

Percival Barretto-Ko

Percival Barretto-Ko

Chief Business Officer, Astellas Pharma Inc.

Percival Barretto-Ko joined the Americares board in 2020. Mr. Barretto-Ko brings to the board extensive experience in the global pharmaceutical industry, including several senior leadership positions in general management, corporate strategy and business development. In his current role, Mr. Barretto-Ko leads the execution of Astellas’ corporate strategic plan and spearheads efforts to enhance internal and external innovation. A member of Astellas’ executive committee, Mr. Barretto-Ko oversees business development, advanced informatics and analytics, intellectual property: innovation and new technologies, patient centricity, information systems, iota biosciences, Rx+ business accelerator and the transformation office.

Previously, Mr. Barretto-Ko served as president of Astellas U.S. In this role, he was responsible for the operations for Astellas Pharma across the United States, with its headquarters in Northbrook, Ill., and more than 3,000 employees. Mr. Barretto-Ko’s earlier roles with the company include senior vice president, head of international, where he led Astellas’ businesses outside of the United States, serving unmet patient needs in over 20 markets, senior vice president, corporate strategy, business development and government affairs, where he led the company’s activities in business development and corporate strategy in Northbrook, Ill., and government affairs in Washington, D.C.

Before joining Astellas, Barretto-Ko held senior positions with the Roche Group in the United States and United Kingdom across various therapeutic areas including oncology, hematology, virology, immunology and infectious diseases.

He earned a bachelor’s degree in biological sciences with honors from Cornell University, an MBA from Yale University and a master’s degree from MIT Sloan School of Management, where he also served as a Sloan Fellow for Innovation and Global Leadership.